Pacific Biosciences of California, Inc. (PACB)
Summary
PACB Chart
People also search for
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity
Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in services revenue, CFO Jim Gibson said during the Canaccord Genuity Growth Conference.
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.
Pacific Biosciences: It's Only Getting Worse
Pacific Biosciences reported Q2 revenues of $39.01 million, missing estimates and guiding 2026 revenues down, below consensus. Operating and net losses remain sizable, with cash now under $237 million and nearly $645 million in debt outstanding. PACB trades at 2.4x expected 2026 revenues, a steep discount to peers, reflecting weaker financials and growth prospects.
Pacific Biosciences of California, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 819 | $1,132.73 | $1,146.6 | $13.87 | 1.22% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 182 | $256.08 | $207.48 | -$48.6 | -18.98% |
 Farallon Capital Farallon Capital Management LLC | 14,200 | $118,570 | $16,330 | -$102,240 | -86.23% |
| NA Nizar Araji National Bank Of Canada /FI/ | 1,037 | $1,389.28 | $1,228.84 | -$160.44 | -11.55% |
| AG Anne Goffard Artal Group S.A. | 200,000 | $340,000 | $222,000 | -$118,000 | -34.71% |
Pacific Biosciences of California, Inc. (PACB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pacific Biosciences of California, Inc. ever had a stock split?
Pacific Biosciences of California, Inc. Profile
| Life Sciences Tools & Services Industry | Healthcare Sector | Mark Van Oene CEO | NASDAQ (NGS) Exchange | 69404D108 CUSIP |
| US Country | 485 Employees | - Last Dividend | - Last Split | 27 Oct 2010 IPO Date |
Overview
Pacific Biosciences of California, Inc., originally known as Nanofluidics, Inc. until its name change in 2005, is a biotechnology firm focused on the design, development, and manufacturing of solutions for sequencing in order to tackle genetically complex problems. Founded in the year 2000 and based in Menlo Park, California, the company has carved a niche for itself in the realm of high-fidelity long-read sequencing technologies. Pacific Biosciences, also known as PacBio, caters to a diverse clienteles such as academic and governmental research institutions, genome centers, public health laboratories, hospitals, clinical research institutes, contract research organizations, as well as entities in the pharmaceutical and agricultural sectors. The company boasts a global presence, marketing its products directly and through distribution partners across Asia, Australia, Europe, the Middle East, Africa, and Latin America. Strategic alliances, like those with Invitae Corporation for development and commercialization, and a collaboration with Radboud University Medical Center for genetics research, are pillars supporting PacBio's innovation and market expansion.
Products and Services
- Sequencing Systems
- Consumable Products
- Binding and Sequencing Kits
- Revio System & Sequel Systems
- Short-Read Sequencing (SBB)
- Onso Instrument & SBB Consumables
Pacific Biosciences offers sequencing systems renowned for their single molecule real-time (SMRT) technology. This technology allows for the resolution of genetically complex issues through high-fidelity, long-read sequencing capabilities.
The company provides a variety of consumable products for sequencing, including SMRT cells, and reagent kits designed for specific workflows. This includes kits for the preparation of SMRTbell double-stranded DNA libraries, which comprise essential molecular biology reagents necessary for sequencing preparation.
PacBio's binding kits include modified DNA polymerase, crucial for binding SMRTbell libraries to the polymerase in preparation for sequencing. Sequencing kits, on the other hand, contain all necessary reagents for on-instrument real-time sequencing, which includes phospholinked nucleotides.
The Revio and Sequel systems are designed for the conduct, monitoring, and analysis of single-molecule biochemical reactions in real-time, pioneering advancements in the sequencing technologies sector.
Beyond its forte in long-read sequencing, Pacific Biosciences also provides solutions for short-read sequencing (SBB), catering to a broader range of genomic analysis needs.
The Onso instrument is tailored for conducting, monitoring, and analyzing SBB biochemical reactions. Accompanying consumables include flow cells and reagent kits for clustering and sequencing, facilitating comprehensive short-read sequencing processes.
